KR20200025093A - Composition for preventing or treating prostatic diseases comprising Stauntonia hexaphylla extract and Cornus officinalis as active ingredients - Google Patents

Abstract

The present invention relates to a composition for preventing or treating prostate diseases, containing a Stauntonia hexaphylla extract and a Cornus officinalis extract as active components. Specifically, a complex extract of Stauntonia hexaphylla and Cornus officinalis has no cytotoxicity and has an excellent effect of inhibiting the expression of an androgen receptor, a prostate specific antigen, and a prostate specific enzyme, thereby being able to be used as an active component of the composition for preventing or treating prostate diseases.

Description

Composition for preventing or treating prostatic diseases comprising Stauntonia hexaphylla extract and Cornus officinalis as active ingredients

The invention meolkkul (Stauntonia Hexaphylla ) and Cornus officinalis Sieb. et Zucc) relates to a composition for the prevention or treatment of prostate disease containing as an active ingredient.

The prostate is an accessory gonad consisting of gland tissue and fibromyalgia, which produces and secretes semen. Prostate fluid produced in the prostate gland provides nutrition to the sperm that is made in the testis and moves, and helps the sperm to exercise actively by maintaining the liquid state so that the ejaculated semen does not harden. Representative prostate disorders include enlarged prostate, prostate cancer and prostatitis.

Benign prostatic hyperplasia (BPH) is one of the most common diseases in adult men, with 50% of men over 50 years old and 80% of men over 80 years old reported the highest frequency of urinary tract disorders. do. The number of patients with prostatic hyperplasia in Korea increased from 45,999 in 2006 to 842,000 in 2011, an increase of 83.5%, and the incidence has recently increased rapidly.

In general, the size of an adult's prostate is about 20g, but when the prostate enlarges to an abnormal size and grows to 40-400g, urinary pressure, urinary frequency, and urinary urine that squeeze the urinary tract at least 8 times a day Symptoms of bladder storage, such as impure urinary urinary tract and urine when urinating, delayed urine when the urine is released, severed urine that interrupts the flow of urine, or the need to give strength during urination Will appear. Patients with prostatic hypertrophy do not need surgical treatment without urinary obstruction or other complications, but about 50% of patients need to be treated by age 80. In addition, some of the patients with prostatic hyperplasia are associated with prostate cancer, which is not a fatal disease in itself, but it is emerging as an important medical problem in the current society entering the aging society because it lowers the quality of life.

Surgical treatment for enlarged prostate was almost performed at the beginning, but since the late 80's, it has been rapidly changed to drug administration. However, the drugs used in the treatment of conventional prostatic hypertrophy have many side effects and are limited in their efficacy, and thus, it is necessary to develop new therapeutic agents having excellent therapeutic effects without causing side effects or drug resistance.

Prostate cancer is the most common cancer among male cancers in the West, and the incidence of prostate cancer is increasing rapidly in Korea. The treatment of prostate cancer differs according to the stage of the disease. Local cancer is treated for the purpose of radical treatment, but metastatic cancer is treated systemically. For the treatment of localized prostate cancer, atmospheric therapy, radical prostatectomy, and radiation therapy may be selected in consideration of the age, health status, sexual function, tumor stage and differentiation, and patient preference. Metastatic prostate cancer can be treated with hormones or with chemotherapy.

Prostatitis is an inflammation of the prostate gland and is so common that about 50% of adult men experience symptoms once in their lifetime. Urinary tract infections are most often caused by direct infection of bacteria through the urethra, and can also be caused by disorders of excretion of prostate fluid, urinary tract flow into the prostate, and transmission of inflammation such as hemorrhoids or colitis.

Since prostate diseases such as prostate cancer, enlarged prostate, and prostatitis are associated with androgen, a male hormone, anti-androgen drugs that inhibit the expression of androgen receptors can provide a therapeutic and prophylactic effect or relief of symptoms. . In addition, prostate specific antigen inhibitors that inhibit the expression of prostate specific antigens are also effective in the prevention and treatment / symptom improvement of the prostate disease affected by prostate specific antigens. In addition, 5-alpha reductase inhibitors that inhibit male hormones have been used for the treatment of male diseases caused by male hormones such as prostatic hypertrophy and hair loss. More specifically, 5-alpha reductase, which converts testosterone, a male hormone, to dihydrotestosterone (DHT), is a microsome's NADPH-dependent 3-oxo-5α-steroid-dehydrogenase, a testosterone-like Reduce the binding steroid. 5-alpha reductase has type 1, type 2, and type 3 subtypes. Type 1 is present in various organs such as skin and liver tissue. Type 2 is mainly present in the urinary tract including the liver and prostate. Testosterone is converted to dihydrotestosterone by at least 90% by 5-alpha reductase in prostate tissue and dihydrotestosterone promotes prostate growth with approximately 10 times more activity of testosterone. Therefore, the efficient inhibition of 5-alpha reductase may reduce the synthesis of physiologically active dihydrotestosterone, which may eventually improve or treat prostatic hyperplasia. In addition, as in the case of prostatic hypertrophy, when dihydrotestosterone is excessively synthesized by 5-alpha reductase, the dihydrotestosterone binds to androgen receptors around the hair follicles, and the hair follicles gradually shrink and deteriorate, causing hair loss. Therefore, it is possible to efficiently inhibit or treat hair loss by effectively inhibiting 5-alpha reductase.

On the other hand, honey can be found in valleys and forests in the southern regions of South Korea such as Jeonnam, Gyeongnam, and Chungnam, and is an evergreen vine plant with creeping vines. The scientific name is Stauntonia Hexaphylla. Stems, leaves, and roots are used as medicinal herbs and are known for their anti-inflammatory, antipyretic, analgesic effects. It can also be used as a cardiac medicine used to return function to normal when the heart is weak or incomplete, or as a diuretic to promote the release of unnecessary water from the body. In addition, it is known to be effective in inhibiting subcutaneous fat accumulation, joint diseases, myoma and facial neuralgia.

Cornus Fructus is Cornus officinalis Siebold et Zuccarini (Cornaceae) is the ripe fruit of the seed removed. It is an irregular piece or bag shape, 10-15 mm long, and about 1 cm wide. The outer surface is dark reddish purple to dark purple with shiny and rough wrinkles. The pulp has seed marks, the upper part of the calyx and the lower part of the fruit stalk. The vagina is soft, has a slight smell, tastes sour and slightly sweet. Cornus milk is known to have diuretic, hypotensive, nourishing, anti-allergic, antihistamine, antiacetylcholine, antibarium and antimicrobial effects.

Therefore, the present inventors tried to develop a natural product-derived prostate disease treatment agent with no side effects as a result of ensuring safety, the honey and corn coriander extract has no cytotoxicity, and inhibits the expression of androgen receptor, prostate specific antigen and prostate specific enzyme. By confirming the superiority, the present invention was completed by revealing that it can be used as an active ingredient of a composition for preventing or treating prostate disease.

Republic of Korea Patent Publication No. 10-2016-0143500

An object of the present invention is meolkkul (Stauntonia Hexaphylla ) and Cornus officinalis Sieb. et Zucc extract to provide a composition for the prevention or treatment of prostate disease, containing as an active ingredient.

In order to achieve the above object, the present invention meolkkul (Stauntonia hexaphylla extract and Cornus officinalis Sieb. et Zucc) provides a pharmaceutical composition for the prevention or treatment of prostate disease, containing the extract as an active ingredient.

The present invention also provides a health food for the prevention or improvement of prostate disease, containing the honey extract and cornus extract as an active ingredient.

In addition, the present invention provides a food composition for the prevention or improvement of prostate disease, containing the honey extract and cornus extract as an active ingredient.

The honey and corn coriander extract of the present invention has no cytotoxicity, and has an excellent inhibitory effect on the expression of androgen receptors, prostate specific antigens and prostate specific enzymes, and thus can be used as an active ingredient for preventing or treating prostate disease.

1 is an extract of the honey ( Stauntonia hexaphylla ) prepared in the embodiment of the present invention in LNCaP cells, cornus ( Cornus) officinalis Sieb. et Zucc) extract, or a combination of honey and cornus extract extract 0, 10, 25, 50 ㎍ / ㎖ after the cytotoxicity was confirmed.
Figure 2 is treated with 1 μM testosterone 1 μM LNCaP cells in the honey extract 25, 50 ㎍ / ㎖, Cornus extract 50 ㎍ / ㎖, or 25 ㎍ / ㎖ of honey and cornus extract extract AR , PSA and 5α-reductase 2 protein expression changes confirmed.

Hereinafter, the present invention will be described in more detail.

The invention meolkkul (Stauntonia It provides a pharmaceutical composition for the prevention or treatment of prostate disease, containing hexaphylla ) extract and Cornus officinalis Sieb. et Zucc extract as an active ingredient.

Each of the honey extract and cornus extract, which are the active ingredients of the present invention, is preferably prepared by a method comprising the following steps, but is not limited thereto:

1) extracting by adding an extraction solvent to each of honey and cornus;

2) filtering the extract of step 1);

3) concentrating the filtrate of step 2) under reduced pressure; And

4) drying the concentrate of step 3).

In the production method of the present invention, the honey or cornus of step 1) can be used without limitation, those grown or commercially available. In addition, the honey may be used for flowers, branches, stems, leaves, fruits, ground, root stems, roots, or a combination thereof, and more specifically, honey leaves of honey.

In the production method of the present invention, the extraction solvent of step 1) is preferably water, alcohol or a mixture thereof. As the alcohol, C ₁ to C ₂ lower alcohols are preferably used, and as lower alcohols, ethanol or methanol is preferably used. As the extraction method, it is preferable to use shaking extraction, Soxhelt extraction or reflux extraction, but is not limited thereto. The extraction solvent is preferably extracted by adding 1 to 20 times the amount of dried honey or cornus oil, more preferably by adding 3 to 17 times, and more preferably by adding 5 to 15 times. . The extraction temperature is preferably 10 to 100, but is not limited thereto. In addition, the extraction time is preferably 1 to 72 hours, but is not limited thereto. In addition, the number of extraction is preferably 1 to 5 times, more preferably 3 to 4 repetitions, even more preferably 3 times, but is not limited thereto.

In the production method of the present invention, the reduced pressure concentration of step 3) is preferably a vacuum reduced pressure concentrator or a vacuum rotary evaporator, but is not limited thereto. In addition, the drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.

In the production method of the present invention, the honey extract and cornus extract may be mixed after the preparation of each extract, it is also possible to be prepared in the form of obtaining the extract after mixing the honey and cornus.

The composition may contain a honey extract: cornus extract in a weight ratio of 5: 5 to 9.5: 0.5, specifically may be contained in a weight ratio of 6: 4 to 9.5: 0.5, more specifically 7: 3: to 9.5: It may be contained in a weight ratio of 0.5, more specifically may be contained in a weight ratio of 8: 2 to 9.5: 0.5, and more specifically may be contained in a weight ratio of 8.5: 2.5 to 9.5: 0.5.

The prostate disease can be, for example, prostate cancer, enlarged prostate or prostatitis.

In a specific embodiment of the present invention, the present inventors prepared honey extract 70% ethanol extract and wild corn 70% ethanol extract, and mixed the extract in various mixing ratios to prepare a complex extract of honey and cornus.

In addition, the present inventors confirmed the cytotoxicity of the honey and cornus extract in the prostate cancer cells, it was confirmed that the complex extract is not cytotoxic at various concentrations (see Figure 1).

In addition, the present inventors confirmed the protein expression of androgen receptor (AR), prostate specific antigen (PSA) and prostate specific enzyme (5α-reductase 2) in prostate cancer cells treated with the honey and cornus complex extract with testosterone, The complex extract was confirmed to have excellent protein, inhibitory effect of AR, PSA and 5α-reductase 2 (see Fig. 2).

Therefore, the present inventors have confirmed that the honey and cornus complex extract of the present invention has no cytotoxicity, and the effect of inhibiting the expression of androgen receptor, prostate specific antigen and prostate specific enzyme, the honey and cornus complex extract of the present invention is prostate disease It can be usefully used as a prophylactic or therapeutic pharmaceutical composition, or as an active ingredient of a male composition caused by testosterone, such as a pharmaceutical composition for preventing or treating hair loss.

The compositions of the present invention may be oral or parenteral (eg, applied or intravenously, subcutaneously, intraperitoneally). Formulations for non-administration may be in the form of powders, granules, tablets, capsules, sterile aqueous solutions, solutions, non-aqueous solutions, suspensions, emulsions, syrups, suppositories, aerosols, etc. It may be used in the formulation, and preferably used to prepare an external skin pharmaceutical composition of creams, gels, patches, sprays, ointments, warnings, lotions, linings, pasta or cataplasma. It is not limited to this. Compositions of topical administration may be anhydrous or aqueous, depending on the clinical prescription. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used. Solid form preparations for oral administration include powders, granules, tablets, capsules, soft capsules, pills and the like. Oral liquid preparations include suspensions, solvents, emulsions, syrups, and aerosols.In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. Can be.

The composition may be prepared by including one or more pharmaceutically acceptable carriers in addition to the active ingredient of the present invention for administration. Pharmaceutically acceptable carriers may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, if necessary, as antioxidants, buffers And other conventional additives such as bacteriostatic agents can be added. In addition, diluents, dispersants, surfactants, binders and lubricants may be additionally added to formulate injectable formulations such as aqueous solutions, suspensions, emulsions and the like.

Pharmaceutically acceptable additives according to the invention are preferably included in an amount of 0.1 to 90 parts by weight based on the composition.

Preferred dosages of the compositions of the present invention vary depending on the degree of absorption of the active ingredient in the body, the age, sex and obesity of the patient, but may be appropriately selected by those skilled in the art. For the desired effect, however, oral dosages generally give the adult composition of the present invention per kg of body weight per day to 0.0001 to 500 mg / kg, preferably 0.001 to 300 mg / kg per day, more preferably. Preferably from 0.01 to 200 mg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.

The present invention also provides a health food for the prevention or improvement of prostate disease, containing the honey extract and cornus extract as an active ingredient.

In addition, the present invention provides a food composition for the prevention or improvement of prostate disease, containing the honey extract and cornus extract as an active ingredient.

The honey extract and cornus extract, the mixing ratio thereof, prostate disease is the same as the description of the pharmaceutical composition for the prevention or treatment of the prostate disease, the specific description is used for the above, and the following specific to health food or food composition Only the configuration will be described.

On the other hand, the honey and corn coriander extract of the present invention has no cytotoxicity, and it was confirmed that the effect of inhibiting the expression of androgen receptors, prostate specific antigens and prostate specific enzymes, the complex extract of the present invention health for the prevention or improvement of prostate disease It can be usefully used as an active ingredient of a food or food composition. In addition, the complex extract of the present invention can be usefully used as an active ingredient of a health food or food composition for preventing or improving hair loss caused by testosterone, such as male disease.

The two extracts of the present invention may be provided as a health food or food composition in admixture with a food acceptable carrier.

The health food of the present invention includes the form of tablets, capsules, pills or liquids.

When the two extracts of the present invention are used as food or beverage additives, the two extracts may be added as they are or used together with other food or food ingredients, and may be suitably used according to conventional methods. The mixed amount of the two extracts may be suitably determined according to the purpose of use (prevention, health or therapeutic treatment). In the case of long-term intake for health and hygiene or health control, the two extracts can be taken for a long time because there is no problem in terms of safety. There is no particular limitation on the kind of the food.

Examples of the food to which the substance may be added include meat, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, teas, and drinks. Alcoholic beverages and vitamin complexes. The liquid component added in addition to the two extracts when formulated into a beverage is not limited to the above, but may contain various flavors or natural carbohydrates, etc. as additional ingredients, as in conventional beverages. Examples of the aforementioned natural carbohydrates include monosaccharides (e.g. glucose, fructose, etc.), disaccharides (e.g. maltose, sucrose, etc.) and polysaccharides (e.g. conventional sugars such as dextrins, cyclodextrins, etc.), and xylitol Sugar alcohols such as sorbitol and erythritol. The proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 mL of the composition of the present invention. As flavoring agents other than those mentioned above, natural flavoring agents (taumarin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (e.g., saccharin, aspartame, etc.) can be used. .

In addition, the food composition of the present invention is a variety of nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (such as cheese, chocolate), pectic acid and salts thereof, organic acids, protection Sex colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like. The food composition of the present invention may also contain pulp for the production of fruit and vegetable drinks. These components may be used alone or in combination, and the ratio of such additives is generally selected in the range of 0.001 to 50 parts by weight per total weight of the composition.

Hereinafter, the present invention will be described in detail by Examples, Experimental Examples and Preparation Examples.

However, the following Examples, Experimental Examples and Preparation Examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following Examples, Experimental Examples, and Preparation Examples.

< Example  1> Honey  Preparation of Extract

Meolkkul dried (Stauntonia hexaphylla ) leaves 20 mL of 70% alcohol in 20 g of the leaves and extracted by cold for 12 hours by sonication (sonication). Thereafter, the obtained extract was filtered through a filter paper, and the filtered residue was further extracted twice with cold extraction with 300 mL of 70% alcohol for 12 hours and filtered. When the extraction was completed, the honey extract was obtained through the manufacturing process of combining the filtrates and concentrated under reduced pressure and lyophilization.

< Example  2> Preparation of Cornus Extract

Dry Cornus ( Cornus) officinalis Sieb. et Zucc) 300 g of 70% alcohol in 20 g was extracted by cold for 12 hours by sonication. Thereafter, the obtained extract was filtered through a filter paper, and the filtered residue was further extracted twice with cold extraction with 300 mL of 70% alcohol for 12 hours and filtered. When the extraction was completed, the filtrate was combined to obtain a cornus extract through a manufacturing process of concentration under reduced pressure and lyophilization.

< Example  3> Honey  And Preparation of Cornus Extract

The honey honey extract obtained in <Example 1> and the cornus extract obtained in the <Example 2> was mixed in the mixing ratio of the following [Table 1] to prepare a honey extract of the honey and cornus.

Example
Extract blend ratio Honey: Cornus 3-1 5: 5 3-2 6: 4 3-3 7: 3 3-4 8: 2 3-5 9: 1

< Experimental Example  1> Honey  Cytotoxicity of Korean and Cornus Extracts

In order to determine the cytotoxicity of the extract of the honey and cornus extract, the survival rate of the prostate cancer cells after treatment with the honey and cornus extract was checked.

Specifically, LNCaP cells (ATCC, USA), a testosterone dependent human prostate cancer cell line, were cultured at 37 ° C. and 5% CO ₂ in RPMI-1640 medium (Gibco) containing 10% FBS (fetal bovine serum). The cultured cells were dispensed in 96 well plates at a concentration of 1 × 10 ⁴ cells / well and incubated for 18 hours under the same conditions. Subsequently, the honeycomb extract prepared in <Example 1>, the cornus extract prepared in <Example 2>, or the honey and cornus extract extract prepared in <Example 3> was added to the cultured cells, respectively, 0 and 10. After treatment at 25 or 50 ㎍ / ㎖ concentration, and further incubated for 72 hours, cell viability assay kit (EX-cytox; DaeiLab Service, Korea) solution was added according to the manufacturer's procedure and 450 using an ELISA reader The absorbance at nm was measured and graphed.

As a result, as shown in Figure 1, it was confirmed that the honey and corn coriander extract is not cytotoxic.

< Experimental Example  1> Honey  And PSA, AR and 5α- of Cornus extract reductase  2 Confirmation of protein expression inhibitory effect

To determine whether the extracts of honey and cornus extracts are effective in the treatment of prostate disease, after treatment of testosterone, honey and cornus extracts on prostate cancer cells, androgen receptor (AR) and prostate specific antigen (PSA), prostate specificity Protein expression of the enzyme (5α-reductase 2) was confirmed.

Specifically, LNCaP cells (ATCC, USA) were dispensed in 6 well plates at a concentration of 5 × 10 ⁴ cells / well and incubated at 37 ° C. for 18 hours. Subsequently, the cultured cells were treated with 1 μM of testosterone, and at the same time, 25 or 50 μg / ml of the honey extract prepared in <Example 1>, 50 μg / ml of the cornus extract prepared in <Example 2>, or After treating at a concentration of 50 ㎍ / ㎖ honey and cornus extract extract prepared in <Example 3> and further culture for 72 hours and harvested. As a positive control (BPH), only 1 μM of testosterone was treated without the extract, and as a control (Fina), 10 μM of finasteride, a prostate hypertrophy treatment, was treated with 1 μM of testosterone instead of the extract. In addition, as a control (sawpal), 100 μg / ml saw palmetto, a prostate hypertrophy treatment, was treated with 1 μM of testosterone instead of the extract. The untreated group was a negative control (Control).

After incubation, the cells were treated with RIPA buffer (50 mM Tris-HCl, pH 8.0, with 150 mM sodium chloride, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate, with a protease inhibitor cocktail). Protein was separated by centrifugation for 20 minutes at a speed of 12,000rpm. The isolated protein was quantified by BCA (Bicinchoninic acid) method.

10 μg of the quantified protein was treated with SDS-PEGE gel, followed by electrophoresis, and the protein was transferred to the PVDF membrane. Thereafter, the PVDF membrane was reacted with 5% skim milk for about 1 hour to remove nonspecific binding proteins on the surface, and the primary antibodies, anti-AR antibody, anti-PSA antibody, anti-5α-reductase 2 antibody, And it was reacted for 1 day at 4 ℃ using an anti-β-actin antibody. After that, the secondary antibody was treated at room temperature for 1 hour, and graphed by confirming the protein expression of AR, PSA and 5α-reductase 2 using an ECL kit (Amersham, UK).

As a result, as shown in Figure 2, the effect of inhibiting AR and PSA protein expression in the cell group treated with 25 ㎍ / ㎖ honey and corn coriander extract compared to the cell group treated with 25 or 50 ㎍ / ㎖ honey extract or cornus extract alone It was confirmed that the remarkably excellent. In addition, it was confirmed that AR and PSA protein expression inhibitory effect was more excellent in the cell group treated with the honey and cornus extract extract in a mixture ratio of 9: 1. In addition, it was confirmed that the effect of inhibiting the expression of 5a-reductase 2 protein in the cell group treated with honey and cornus extract.

The preparation examples for the compositions of the present invention are illustrated below.

Preparation Example 1 Preparation of Pharmaceutical Formulation

<1-1> Preparation of Powder

10 mg complex extract of the present invention

1 g lactose

The above ingredients were mixed and filled in airtight cloth to prepare a powder.

<1-2> Preparation of Tablet

0.1 mg complex extract of the present invention

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

<1-3> Preparation of Capsule

0.1 mg complex extract of the present invention

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.

<1-4> Preparation of the ring

1 mg complex extract of the present invention

Lactose 1.5 g

1 g of glycerin

Xylitol 0.5 g

After mixing the above components, it was prepared to be 4 g per ring in a conventional manner.

<1-5> Preparation of Granules

0.15 mg complex extract of the present invention

Soybean Extract 50 mg

Glucose 200 mg

Starch 600 mg

After mixing the above ingredients, 100 mg of 30% ethanol was added and dried at 60 ° C. to form granules and then filled into fabrics.

Preparation Example 2 Preparation of Health Food

Foods containing the complex extract of the present invention as an active ingredient were prepared as follows.

<2-1> Preparation of Flour Food

0.5 to 5.0 parts by weight of the composite extract of the present invention was added to the flour and bread, cake, cookies, crackers and noodles were prepared using this mixture.

<2-2> soup  And preparation of gravy

0.1 to 5.0 parts by weight of the complex extract of the present invention was added to soups and broth to prepare meat products for health promotion, soup of noodles and broth.

<2-3> ground Ground beef  Produce

10 parts by weight of the complex extract of the present invention was added to ground beef to prepare a ground beef for health promotion.

<2-4> Production of Dairy Products

5 to 10 parts by weight of the complex extract of the present invention was added to milk, and the milk was used to prepare various dairy products such as butter and ice cream.

<2-5> Linear  Produce

Brown rice, barley, glutinous rice, and yulmu were alphad by a known method, and then dried and roasted to prepare a powder having a particle size of 60 mesh.

Black beans, black sesame seeds, and perilla were also steamed and dried in a known manner, and then roasted to prepare a powder having a particle size of 60 mesh.

The complex extract of the present invention was concentrated under reduced pressure in a vacuum concentrator, and the dried product obtained by drying with a sprayer and a hot air dryer was pulverized with a particle size of 60 mesh to obtain a dry powder.

The grains, seeds and the composite extract of the present invention prepared above were formulated in the following ratio.

Cereals (30 parts by weight brown rice, 15 parts by weight brittle, 20 parts by weight of barley),

Seeds (7 parts by weight perilla, 8 parts by weight black beans, 7 parts by weight black sesame seeds),

Complex extract of the present invention (3 parts by weight),

Ganoderma lucidum (0.5 parts by weight),

Foxglove (0.5 weight part)

< Production Example  3> Health drink  Produce

<3-1> Health drink  Produce

Instant sterilization by homogeneously mixing 0.5 g of the complex extract of the present invention with subsidiary materials such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%) and water (75%). Then it was prepared by packaging in a small packaging container such as glass bottles, plastic bottles.

<3-2> Preparation of Vegetable Juice

0.5 g of the complex extract of the present invention was added to 1,000 mL of tomato or carrot juice to prepare vegetable juice.

<3-3> Preparation of Fruit Juice

0.1 g of the complex extract of the present invention was added to 1,000 mL of apple or grape juice to prepare a fruit juice.

Claims (9)

Honey ( Stauntonia) hexaphylla extract and Cornus officinalis Sieb. et Zucc) A pharmaceutical composition for preventing or treating prostate disease, comprising the extract as an active ingredient.
The method of claim 1, wherein the extract is characterized in that extracted with water, C ₁ to C ₂ lower alcohol or a mixed solvent thereof, a pharmaceutical composition for preventing or treating prostate disease.
The method of claim 2, wherein the extract is water, methanol, ethanol and a pharmaceutical composition for the prevention or treatment of prostate disease, characterized in that extracted with one or more solvents selected from the group consisting of these.
The method of claim 1, wherein the extract is characterized in that the extract of any one or more selected from flowers, branches, stems, leaves, fruits, ground, rhizome and root, pharmaceutical composition for preventing or treating prostate disease.
The pharmaceutical composition for preventing or treating prostate disease according to claim 1, wherein the composition contains honey extract: cornus extract in a weight ratio of 5: 5 to 9.5: 0.5.
The pharmaceutical composition for preventing or treating prostate disease according to claim 1, wherein the composition contains honey extract: cornus extract in a weight ratio of 6: 4 to 9.5: 0.5.
According to claim 1, wherein the prostate disease is characterized in that selected from the group consisting of prostate cancer, prostatic hyperplasia and prostatitis, prophylactic or therapeutic pharmaceutical composition for the disease.
Health food for the prevention or improvement of prostate disease, containing the honey extract and cornus extract as an active ingredient.
Food composition for the prevention or improvement of prostate disease, comprising a honey extract and cornus extract as an active ingredient.

Images